FLGT - Is Fulgent Genetics Undervalued?
Fulgent Genetics (NASDAQ: FLGT) looks poised to significantly beat its year-end investor estimates. In this Motley Fool Live video recorded on November 15 , Motley Fool contributors Keith Speights and Brian Orelli answer a viewer question about whether this means Fulgent is undervalued.
With the vast majority of the company's third-quarter revenue coming from COVID-19 testing rather than its core business and considering the general uncertainty over how COVID-19 will progress, it's understandable that investors would discount the current revenue. However, Fulgent seems to be preparing well for a gradual decline in COVID-testing revenue.
For further details see:
Is Fulgent Genetics Undervalued?